|
Cyclophosphamide
N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
C7H15Cl2N2O2P
CAS number 50-18-0;
PubChem
2907.
|
�This exciting Mayo Clinic work supported the
initiation of our combination REOLYSIN� and cyclophosphamide clinical
trial, recently approved by the U.K. health authorities,� said Dr.
Matt Coffey, Chief Scientific Officer of Oncolytics.
The purpose of the research study was to investigate whether it was
possible to use cyclophosphamide, an immune modulator, to enhance the
delivery and replication of the reovirus when delivered intravenously.
After testing various doses and dosing regimens of reovirus and
cyclophosphamide in mice, a metronomic dosing regimen was developed
that resulted in increased survival, high levels of reovirus recovered
from regressing tumors, levels of neutralizing antibodies that were
protective, and only very mild toxicities. The data support
investigation in human clinical trials of the use of cyclophosphamide
prior to systemic reovirus administration to modulate, but not ablate,
the immune system.
Oncolytics Biotech Inc. is a Calgary-based biotechnology company
focused on the development of oncolytic viruses as potential cancer
therapeutics. Oncolytics� clinical program includes a variety of Phase
I and Phase II human trials using REOLYSIN�, its proprietary
formulation of the human reovirus, alone and in combination with
radiation or chemotherapy.
This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including the implication of the
materials presented in �Clinical Cancer Research� with respect to
REOLYSIN�, the Company�s expectations related to the results of trials
investigating delivery of REOLYSIN�, and the Company�s belief as to
the potential of REOLYSIN� as a cancer therapeutic, involve known and
unknown risks and uncertainties, which could cause the Company�s
actual results to differ materially from those in the forward-looking
statements. Such risks and uncertainties include, among others, the
availability of funds and resources to pursue research and development
projects, the efficacy of REOLYSIN� as a cancer treatment, the success
and timely completion of clinical studies and trials, the Company�s
ability to successfully commercialize REOLYSIN�, uncertainties related
to the research and development of pharmaceuticals and uncertainties
related to the regulatory process. Investors should consult the
Company�s quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward-looking statements. Investors
are cautioned against placing undue reliance on forward-looking
statements. The Company does not undertake to update these
forward-looking statements.
|
